

Drug Development for NASH and obesity

Yonsei University



METABOLIC	Hit
Product Type	Peptide
Indication	JP0645
Target	NASH and Obesity
MoA(Mechanism of Action)	Anti-obesity, Anti-inflammation, Anti-fibrosis
Competitiveness	GLP-1 or GLP-1 derivatives
Development Stage	Hit
Route of Administration	intraperitoneal